Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Linezolid: safety and efficacy monitoring

Rupak Singla, Jose A. Caminero, Ashish Jaiswal, Neeta Singla, Sanjay Gupta, Roseleen Kaur Bali, Digambar Behera
European Respiratory Journal 2012 39: 1276-1277; DOI: 10.1183/09031936.00224611
Rupak Singla
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose A. Caminero
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashish Jaiswal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neeta Singla
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjay Gupta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roseleen Kaur Bali
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Digambar Behera
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dirlrsi@bol.net.in
  • Article
  • Info & Metrics
  • PDF
Loading

From the authors:

We read with interest the comments by M.S. Bolhuis and co-workers on our article discussing the role of linezolid in treating multidrug-resistant (MDR) tuberculosis (TB) failures in India [1]. First, we would like to underline that our study was carried out in field conditions in a country with a high burden of MDR-TB cases and limited resources. We thank M.S. Bolhuis and co-workers for the opportunity to discuss the different perspectives of the Indian setting and those of a high-level tertiary hospital in a high-income country (India has one of the best existing TB control programmes).

M.S. Bolhuis and co-workers correctly conclude that only a randomised trial comparing linezolid versus a placebo, in addition to an adequate background regimen using drug susceptibility testing (DST) and therapeutic drug monitoring (TDM), would provide comprehensive results on efficacy and safety of linezolid. However, we have three main comments.

First of all, although the best way to provide high-quality data on the possible efficacy of a drug (or a combination of drugs) in TB treatment is to perform a randomised clinical trial (RCT), this is particularly complicated to organise in the treatment of patients affected by MDR-TB, and is even more complicated if they have previously been exposed to second-line anti-TB drugs (SLDs).

In fact, to date, no RCT has been developed showing the possible efficacy of any of the drugs presently used in the treatment of the MDR-TB patients [2], including fluoroquinolones and injectable antimycobacterial agents (which are presently recommended by the World Health Organization) [3].

Among the key difficulties to mention are the ethical issues related to randomisation of MDR-TB patients receiving SLDs when only a few drugs are still effective (e.g. in extensively drug-resistant TB cases and those failures who had been previously exposed to several cycles of treatment with different drugs) and the difficulty in attributing a specific outcome to a specific drug composing the prescribed cocktail merit a special discussion [2, 3].

Secondly, DST for linezolid has not been standardised and is difficult to perform both in low- and high-income countries, so that its clinical reliability is still largely unknown. There is still much debate over whether in vitro results can be extrapolated to a clinical response [4].

Thirdly, although important, performing linezolid TDM systematically in all patients receiving the drug is unrealistic in India, although it is recommendable in high-level reference centres located in high-income countries [5].

Based on the comments above, we reinforce the reason why we used the word “could”: “Linezolid could have played a key role” [1]. We cannot be totally sure that we are correct in attributing the encouraging outcome of our patients to linezolid only.

Although we agree on the importance of implementing directly observed therapy, this was not unfortunately possible for all cases treated in our setting. An argument indirectly demonstrating that the patients belonging to our cohort received the drugs is that treatment outcomes were satisfactory. This is why we still believe that the low proportion of adverse events is not a consequence of poor compliance.

We have a last comment on price and quality of drugs. It is well known that the price of drugs is largely influenced by the market location and by many other factors, so that a lower cost in India is not necessarily associated with lower quality. Indian manufacturers producing the drug we used in our study are subject to quality controls according to the national legislation in force, including the approval of the Drug Controller General of India before marketing. Also, as discussed above, the positive outcome achieved indirectly demonstrates the drug was active.

In conclusion, although our study [1] is affected by several limitations, it represents a useful contribution to support those clinicians who are dealing with difficult-to-treat MDR-TB patients daily, those desperately needing linezolid as a third or fourth active drug, and those designing an effective regimen. We agree that more evidence on linezolid efficacy, safety and tolerability is necessary: any well-designed study shedding light on the topic will be most welcome.

Footnotes

  • Statement of Interest

    None declared.

  • ©ERS 2012

REFERENCES

  1. ↵
    1. Singla R,
    2. Caminero JA,
    3. Jaiswal A,
    4. et al
    . Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. Eur Respir J 2012; 39: 956–962.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Caminero JA,
    2. Sotgiu G,
    3. Zumla A,
    4. et al
    . Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621–629.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Falzon D,
    2. Jaramillo E,
    3. Schünemann HJ,
    4. et al
    . WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516–528.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Kim SJ
    . Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005; 25: 564–569.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. De Lorenzo S,
    2. Centis R,
    3. D’Ambrosio L,
    4. et al
    . On linezolid efficacy and tolerability. Eur Respir J 2012; 39: 770–772.
    OpenUrlFREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 39 Issue 5 Table of Contents
European Respiratory Journal: 39 (5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Linezolid: safety and efficacy monitoring
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Linezolid: safety and efficacy monitoring
Rupak Singla, Jose A. Caminero, Ashish Jaiswal, Neeta Singla, Sanjay Gupta, Roseleen Kaur Bali, Digambar Behera
European Respiratory Journal May 2012, 39 (5) 1276-1277; DOI: 10.1183/09031936.00224611

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Linezolid: safety and efficacy monitoring
Rupak Singla, Jose A. Caminero, Ashish Jaiswal, Neeta Singla, Sanjay Gupta, Roseleen Kaur Bali, Digambar Behera
European Respiratory Journal May 2012, 39 (5) 1276-1277; DOI: 10.1183/09031936.00224611
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Treatable traits in ILD: why not consider acute exacerbations?
  • Inclusion of lung health outcomes in TB treatment trials
  • Understanding confounding in Mendelian randomisation studies
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society